PMID- 30548112
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20210109
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 110
IP  - 2
DP  - 2019 Feb
TI  - Sine oculis homeobox 1 promotes proliferation and migration of human colorectal 
      cancer cells through activation of Wnt/beta-catenin signaling.
PG  - 608-616
LID - 10.1111/cas.13905 [doi]
AB  - Sine oculis homeobox 1 (Six1) is a homeodomain transcription factor that is 
      aberrantly expressed in a variety of human cancers, including colorectal cancer 
      (CRC). Six1 has been reported to play a key role in the proliferation and 
      migration of CRC cells but the underlying molecular mechanisms are still poorly 
      characterized. In the present study, we found that Six1 overexpression promoted 
      the proliferation and migration of CRC cells. Consistently, Six1 knockdown (KD) 
      significantly inhibited proliferation and migration of CRC cells. In addition, we 
      showed that Six1 promoted proliferation and migration of CRC cells through 
      activation of Wnt/beta-catenin signaling, as evidenced by promotion of nuclear 
      localization of beta-catenin. Silencing of beta-catenin expression with siRNA or 
      inhibiting Wnt signaling with a specific inhibitor, xav939, significantly blocked 
      Six1-induced nuclear localization of beta-catenin and mitigated Six1-promoted 
      proliferation and migration of CRC cells. We further confirmed the involvement of 
      beta-catenin in Six1-promoted proliferation and migration of CRC cells by activation 
      of Wnt signaling with lithium chloride (LiCl) in Six1 KD CRC cells and results 
      showed that LiCl restores defective beta-catenin nuclear localization and 
      proliferation and migration of CRC cells. Taken together, these results suggest 
      that Six1 homeoprotein promotes the proliferation and migration of CRC cells by 
      activating the Wnt/beta-catenin signaling pathway, and strategies targeting Six1 may 
      be promising for the treatment of CRC.
CI  - (c) 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Song, Wenxin
AU  - Song W
AD  - School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, 
      China.
AD  - Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory 
      Medicine, Xinxiang Medical University, Xinxiang, China.
FAU - Ma, Jian
AU  - Ma J
AD  - School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, 
      China.
FAU - Lei, Bingbing
AU  - Lei B
AD  - School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, 
      China.
FAU - Yuan, Xin
AU  - Yuan X
AD  - School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, 
      China.
FAU - Cheng, Binfeng
AU  - Cheng B
AD  - School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, 
      China.
FAU - Yang, Haijie
AU  - Yang H
AD  - School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, 
      China.
FAU - Wang, Mian
AU  - Wang M
AD  - School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, 
      China.
FAU - Feng, Zhiwei
AU  - Feng Z
AD  - School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, 
      China.
AD  - Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory 
      Medicine, Xinxiang Medical University, Xinxiang, China.
FAU - Wang, Lei
AU  - Wang L
AUID- ORCID: 0000-0003-2678-2533
AD  - School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, 
      China.
LA  - eng
GR  - U1604166/National Natural Science Foundation of China/
GR  - 81403161/National Natural Science Foundation of China/
GR  - 201708410350/China Scholarship Council/
PT  - Journal Article
DEP - 20190128
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Homeodomain Proteins)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (SIX1 protein, human)
RN  - 0 (beta Catenin)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Movement/*genetics
MH  - Cell Proliferation/*genetics
MH  - Colorectal Neoplasms/*genetics
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - HCT116 Cells
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - RNA, Small Interfering/genetics
MH  - Signal Transduction/genetics
MH  - Wnt Signaling Pathway/*genetics
MH  - beta Catenin/*genetics
PMC - PMC6361609
OTO - NOTNLM
OT  - Six1
OT  - colorectal cancer
OT  - migration
OT  - proliferation
OT  - beta-catenin
EDAT- 2018/12/15 06:00
MHDA- 2019/02/12 06:00
PMCR- 2019/02/01
CRDT- 2018/12/15 06:00
PHST- 2018/07/30 00:00 [received]
PHST- 2018/11/29 00:00 [revised]
PHST- 2018/12/02 00:00 [accepted]
PHST- 2018/12/15 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
PHST- 2018/12/15 06:00 [entrez]
PHST- 2019/02/01 00:00 [pmc-release]
AID - CAS13905 [pii]
AID - 10.1111/cas.13905 [doi]
PST - ppublish
SO  - Cancer Sci. 2019 Feb;110(2):608-616. doi: 10.1111/cas.13905. Epub 2019 Jan 28.